Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

56,974 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Model-Informed Drug Development for Ixazomib, an Oral Proteasome Inhibitor.
Gupta N, Hanley MJ, Diderichsen PM, Yang H, Ke A, Teng Z, Labotka R, Berg D, Patel C, Liu G, van de Velde H, Venkatakrishnan K. Gupta N, et al. Among authors: yang h. Clin Pharmacol Ther. 2019 Feb;105(2):376-387. doi: 10.1002/cpt.1047. Epub 2018 Mar 23. Clin Pharmacol Ther. 2019. PMID: 29446068 Free PMC article. Review.
A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end-stage renal disease requiring haemodialysis.
Gupta N, Hanley MJ, Harvey RD, Badros A, Lipe B, Kukreti V, Berdeja J, Yang H, Hui AM, Qian M, Zhang X, Venkatakrishnan K, Chari A. Gupta N, et al. Among authors: yang h. Br J Haematol. 2016 Sep;174(5):748-59. doi: 10.1111/bjh.14125. Epub 2016 May 16. Br J Haematol. 2016. PMID: 27196567 Free PMC article. Clinical Trial.
A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis.
Sanchorawala V, Palladini G, Kukreti V, Zonder JA, Cohen AD, Seldin DC, Dispenzieri A, Jaccard A, Schönland SO, Berg D, Yang H, Gupta N, Hui AM, Comenzo RL, Merlini G. Sanchorawala V, et al. Among authors: yang h. Blood. 2017 Aug 3;130(5):597-605. doi: 10.1182/blood-2017-03-771220. Epub 2017 May 26. Blood. 2017. PMID: 28550039 Free PMC article. Clinical Trial.
TAK-264 (MLN0264) in Previously Treated Asian Patients with Advanced Gastrointestinal Carcinoma Expressing Guanylyl Cyclase C: Results from an Open-Label, Non-randomized Phase 1 Study.
Bang YJ, Takano T, Lin CC, Fasanmade A, Yang H, Danaee H, Asato T, Kalebic T, Wang H, Doi T. Bang YJ, et al. Among authors: yang h. Cancer Res Treat. 2018 Apr;50(2):398-404. doi: 10.4143/crt.2017.074. Epub 2017 May 10. Cancer Res Treat. 2018. PMID: 28494535 Free PMC article. Clinical Trial.
A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C.
Almhanna K, Wright D, Mercade TM, Van Laethem JL, Gracian AC, Guillen-Ponce C, Faris J, Lopez CM, Hubner RA, Bendell J, Bols A, Feliu J, Starling N, Enzinger P, Mahalingham D, Messersmith W, Yang H, Fasanmade A, Danaee H, Kalebic T. Almhanna K, et al. Among authors: yang h. Invest New Drugs. 2017 Oct;35(5):634-641. doi: 10.1007/s10637-017-0473-9. Epub 2017 May 19. Invest New Drugs. 2017. PMID: 28527133 Clinical Trial.
Corrigendum: Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease.
Rosario M, French JL, Dirks NL, Sankoh S, Parikh A, Yang H, Danese S, Colombel JF, Smyth M, Sandborn WJ, Feagan BG, Reinisch W, Sands BE, Sans M, Fox I. Rosario M, et al. Among authors: yang h. J Crohns Colitis. 2018 Mar 28;12(4):510. doi: 10.1093/ecco-jcc/jjx168. J Crohns Colitis. 2018. PMID: 29385425 No abstract available.
56,974 results
You have reached the last available page of results. Please see the User Guide for more information.